In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of GeneDx Holdings Corp (NASDAQ: WGS) closed at $151.51 in the last session, down -2.48% from day before closing price of $155.37. In other words, the price has decreased by -$2.48 from its previous closing price. On the day, 0.51 million shares were traded. WGS stock price reached its highest trading level at $157.15 during the session, while it also had its lowest trading level at $149.0701.
Ratios:
We take a closer look at WGS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 28.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 283.09. For the most recent quarter (mrq), Quick Ratio is recorded 2.59 and its Current Ratio is at 2.71. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 20, 2025, initiated with a Buy rating and assigned the stock a target price of $155.
On July 09, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $110.
On May 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $88.Guggenheim initiated its Buy rating on May 15, 2025, with a $88 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 09 ’25 when Feeley Kevin sold 1,266 shares for $159.28 per share. The transaction valued at 201,648 led to the insider holds 5,389 shares of the business.
Stueland Katherine sold 3,639 shares of WGS for $579,620 on Dec 09 ’25. The CHIEF EXECUTIVE OFFICER now owns 6,344 shares after completing the transaction at $159.28 per share. On Dec 01 ’25, another insider, Feeley Kevin, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 377 shares for $162.54 each. As a result, the insider received 61,276 and left with 4,193 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 4379334144 and an Enterprise Value of 4337416192. As of this moment, GeneDx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2512.60, and their Forward P/E ratio for the next fiscal year is 345.49. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.89 while its Price-to-Book (P/B) ratio in mrq is 14.98. Its current Enterprise Value per Revenue stands at 10.784 whereas that against EBITDA is 125.131.
Stock Price History:
The Beta on a monthly basis for WGS is 2.05, which has changed by 0.93006206 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $170.87, while it has fallen to a 52-week low of $55.17. The 50-Day Moving Average of the stock is 9.54%, while the 200-Day Moving Average is calculated to be 43.62%.
Shares Statistics:
According to the various share statistics, WGS traded on average about 516.55K shares per day over the past 3-months and 373900 shares per day over the past 10 days. A total of 28.89M shares are outstanding, with a floating share count of 25.37M. Insiders hold about 12.23% of the company’s shares, while institutions hold 103.73% stake in the company. Shares short for WGS as of 1764288000 were 3594043 with a Short Ratio of 6.96, compared to 1761868800 on 3504577. Therefore, it implies a Short% of Shares Outstanding of 3594043 and a Short% of Float of 24.77.
Earnings Estimates
The dynamic stock of GeneDx Holdings Corp (WGS) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.0, with high estimates of $0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between $1.47 and $1.29 for the fiscal current year, implying an average EPS of $1.38. EPS for the following year is $0.43, with 7.0 analysts recommending between $0.74 and $0.09.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $120.49M. It ranges from a high estimate of $122.1M to a low estimate of $119.2M. As of. The current estimate, GeneDx Holdings Corp’s year-ago sales were $95.64MFor the next quarter, 8 analysts are estimating revenue of $117.79M. There is a high estimate of $119.8M for the next quarter, whereas the lowest estimate is $115.4M.
A total of 9 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $428.7M, while the lowest revenue estimate was $425.7M, resulting in an average revenue estimate of $427.04M. In the same quarter a year ago, actual revenue was $305.45MBased on 9 analysts’ estimates, the company’s revenue will be $529.27M in the next fiscal year. The high estimate is $545.6M and the low estimate is $506.6M.
